PU-71 treatment markedly suppressed the survival and metastatic ability of ES cells through inhibition of IGF-1R, AKT, and pERK activation, as well as downregulation of RAF-1, c-MYC, c-KIT, IGF1R, hTERT, and EWS-FLI1 expression. The gene discussed is FLI1; the disease is Ewing sarcoma.